[1]高天雨,关徐涛,刘瑞宝,等.基于GBD数据库中国青光眼流行病学负担分析[J].眼科新进展,2024,44(5):382-386.[doi:10.13389/j.cnki.rao.2024.0074]
　GAO Tianyu,GUAN Xutao,LIU Ruibao,et al.Epidemiological burden of glaucoma in China based on Global Burden of Disease database[J].Recent Advances in Ophthalmology,2024,44(5):382-386.[doi:10.13389/j.cnki.rao.2024.0074]
点击复制

基于GBD数据库中国青光眼流行病学负担分析/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
44卷
期数:
2024年5期
页码:
382-386
栏目:
应用研究
出版日期:
2024-04-30

文章信息/Info

Title:
Epidemiological burden of glaucoma in China based on Global Burden of Disease database
作者:
高天雨; 关徐涛; 刘瑞宝; 杨稀瑞
450000　河南省郑州市，河南中医药大学第一临床医学院（高天雨，关徐涛，刘瑞宝）；450000　河南省郑州市，河南中医药大学第一附属医院眼科（杨稀瑞）
Author(s):
GAO Tianyu1; GUAN Xutao2; LIU Ruibao2; YANG Xirui2
1.The First Clinical School of Henan University of Traditional Chinese Medicine，Zhengzhou 450000，Henan Province,China
2.Department of Ophthalmology，the First Affiliated Hospital of Henan University of Traditional Chinese Medicine，Zhengzhou 450000，Henan Province，China
关键词:
青光眼; 中国; 疾病负担; 全球疾病负担数据库
Keywords:
glaucoma;  China;  disease burden;  Global Burden of Disease database
分类号:
R775
DOI:
10.13389/j.cnki.rao.2024.0074
文献标志码:
A
摘要:
目的　下载全球疾病负担（GBD）数据库中中国青光眼的相关数据，分析中国青光眼的疾病流行病学负担，从而为中国青光眼防控提供理论依据。
方法　下载GBD（2019）数据库中患病人数、患病率、伤残调整寿命年（DALYs）/DALY率的相关数据，分析中国1990—2019年青光眼流行趋势及年龄、时期、性别趋势和青光眼与社会人口指数(SDI)之间的关系。
结果　2019年，中国青光眼粗患病人数位于全球首位，中国青光眼导致的DALYs位于全球第二。2019年，中国青光眼患病率位于全球高水平，患病人数为1990年的1.92倍，患病率及DALY率均持续上升；中国青光眼患病人数年龄趋势呈中间高、两头低形态，且男性高于女性，随着SDI的增长，年龄标化患病率和DALY率均呈现降低趋势，平均年度变化百分比均为负数。患病人数的年龄趋势呈现中间高、两边低的形态。随着SDI的增长，年龄标化患病率和DALY率整体呈现降低趋势，平均年度变化百分比均为负数。
结论　1990—2019年间，中国青光眼疾病负担显著上升，居全球前列，且与社会发展程度呈正相关。
Abstract:
Objective　To analyze the epidemiological burden of glaucoma in China based on data from the Global Burden of Disease 2019 (GBD 2019) database to provide a theoretical basis for the prevention and control of glaucoma in China.
Methods　Analysis of the glaucoma epidemic trend and age, period, and gender trends in China from 1990 to 2019 and the correlation between glaucoma and the Socio-Demographic Index (SDI) were conducted according to relevant data on the number of patients, prevalence, disability-adjusted life years (DALYs) and DALY rates downloaded from the GBD 2019 database.
Results　In 2019, China was ranked globally first for the number of people with glaucoma and second for DALYs due to glaucoma. In 2019, China’s glaucoma prevalence was among the highest globally, with the number of patients being 1.92 times that of 1990. Both the prevalence and the DALY rate demonstrated a persistent upward trajectory. The demographic distribution of patients with glaucoma in China revealed a curve which peaked among middle-aged individuals,with higher prevalence observed in males than females. An inverse correlation was identified between SDI and the age-standardized prevalence and DALY rates, which exhibited a negative average annual percentage change, indicative of a progressive decline with rising SDI.
Conclusion　From 1990 to 2019, China experienced a significant increase in the burden of glaucoma, ranking among the highest globally, with a positive correlation observed between the disease burden and the level of social development.

参考文献/References:

［1］　中华医学会眼科学分会青光眼学组,中国医师协会眼科医师分会青光眼学组.中国青光眼指南(2020年)［J］.中华眼科杂志,2020,56(8):573-586.
The Glaucoma Group of the Ophthalmology Branch of the Chinese Medical Association,the Glaucoma Group of the Ophthalmology Branch of the Chinese Medical Association.China glaucoma guide (2020)［J］.Chin J Ophthalmol,2020,56(8):573-586.
［2］　LIU W,GUO R,HUANG D,JI J,GANSEVOORT R T,SNIEDER H,et al.Co-occurrence of chronic kidney disease and glaucoma:Epidemiology and etiological mechanisms［J］.Surv Ophthalmol,2023,68(1):1-16.
［3］　THAM Y C,LI X,WONG T Y,QUIGLEY H A,AUNG T,CHENG C Y.Global prevalence of glaucoma and projections of glaucoma burden through 2040:a systematic review and meta-analysis［J］.Ophthalmology,2014,121(11):2081-2090.
［4］　梁远波,江俊宏.我国青光眼防治问题与展望［J］.浙江医学,2020,42(22):2377-2382.
LIANG Y B,JIANG J H.Problems and prospects of glaucoma prevention and treatment in China［J］.Zhejiang Med J,2020,42(22):2377-2382.
［5］　邓柔,吴艳霞,路雪婧.针刺治疗青光眼的研究进展［J］.中国中医眼科杂志,2023,33(3):282-285.
DENG R,WU Y X,LU X J.Research progress of acupuncture in the treatment of glaucoma［J］.CHN J Chin Ophthalmol,2023,33(3):282-285.
［6］　BARAYEV E,GEFFEN N,NAHUM Y,GERSHONI A.Changes in prices and eye-care providers prescribing patterns of glaucoma medications in the United States between 2013 and 2019［J］.J Glaucoma,2021,30(3):e83-e89.
［7］　PATEL A R,SCHWARTZ G F,CAMPBELL J H,CHEN C C,MCGUINESS C B,MULTANI J K,et al.Economic and clinical burden associated with intensification of glaucoma topical therapy:a US claims-based analysis［J］.J Glaucoma,2021,30(3):242-250.
［8］　宇传华,白建军.社会人口指数(SDI)的概念及其应用［J］.公共卫生与预防医学,2020,31(1):5-10.
YU C H,BAI J J.The concept of socio-demographic index (SDI) and its application［J］.J Public Health Prev Med,2020,31(1):5-10.
［9］　潘政,江冰.青光眼的危险因素和预防［J］.家庭医学(下半月),2021(2):18-19.
PAN Z,JIANG B.Risk factors and prevention of glaucoma［J］.Fam Med,2021(2):18-19.
［10］　YADAV M,BHARDWAJ A,YADAV A,DADA R,TANWAR M.Molecular genetics of primary open-angle glaucoma［J］.Indian J Ophthalmol,2023,71(5):1739-1756.
［11］　LIUSKA P J,HARJU M,KIVEL T T,TURUNEN J A.Prevalence of MYOC risk variants for glaucoma in different populations［J］.Acta Ophthalmol,2021,99(7):e1090-e1097.
［12］　MORENO-MONTAS J,GNDARA E,GUTIERREZ-RUIZ I,MORENO-GALARRAGA L,RUIZ-CANELA M,BES-RASTROLLO M,et al.Healthy lifestyle score and incidence of glaucoma:the Sun Project［J］.Nutrients,2022,14(4):779.
［13］　JUNG Y,HAN K,PARK H Y L,LEE S H,PARK C K.Metabolic health,obesity,and the risk of developing open-angle glaucoma:metabolically healthy obese patients versus metabolically unhealthy but normal weight patients［J］.Diabetes Metab J,2020,44(3):414-425.
［14］　JOSHI R S,ADATIYA V H.Study of the relationship between serum lipid levels and primary open-angle glaucoma［J］.Indian J Ophthalmol,2023,71(5):1948-1952.
［15］　RODDY G W.Metabolic syndrome and the aging retina［J］.Curr Opin Ophthalmol,2021,32(3):280-287.
［16］　LIMA-FONTES M,BARATA P,FALCO M,CARNEIRO .Ocular findings in metabolic syndrome:a review［J］.Porto Biomed J,2020,5(6):e104.
［17］　ZHANG Z Q,XIE Z,CHEN S Y,ZHANG X.Mitochondrial dysfunction in glaucomatous degeneration［J］.Int J Ophthalmol,2023,16(5):811-823.
［18］　闫慧敏,张梅,张笑,夏云婷,申涛,赵振平,等.中国老年人代谢综合征流行特征及其影响因素研究［J］.中华高血压杂志,2019,27(11):1100.
YAN H M,ZHANG M,ZHANG X,XIA Y T,SHEN T,ZHAO Z P,et al.Study of epidemiological characteristics of metabolic syndrome and influencing factors in elderly people in China［J］.Chin J Hypertens,2019,27(11):1100.
［19］　TOMASONI M,BEYELER M J,VELA S O,MOUNIER N,PORCU E,CORRE T,et al.Genome-wide association studies of retinal vessel tortuosity identify numerous novel loci revealing genes and pathways associated with ocular and cardiometabolic diseases［J］.Ophthalmol Sci,2023,3(3):100288.
［20］　KORPOLE N R,KURADA P,KORPOLE M R.Gender difference in ocular diseases,risk factors and management with specific reference to role of sex steroid hormones［J］.J Midlife Health,2022,13(1):20-25.
［21］　MADJEDI K M,STUART K V,CHUA S Y L,FOSTER P J,STROUTHIDIS N G,LUBEN R N,et al.The association of female reproductive factors with glaucoma and related traits:a systematic review［J］.Ophthalmol Glaucoma,2022,5(6):628-647.
［22］　林艳辉,高莉茉,姜文敏.基于GBD数据库中国年龄相关性黄斑变性流行病学负担分析［J］.中南大学学报(医学版),2023,48(1):106-113.
LIN Y H,GAO L M,JIANG W M.Analysis of the epidemiological burden of age-related macular degeneration in China based on the data of global burden of disease［J］.J Cent South Univ Med Sci,2023,48(1):106-113.
［23］　夏笑清,赵岩,郝萌萱,王仪伟,万霞,王增武,等.1990年和2019年中国与世界不同社会人口学指数地区居民焦虑症疾病负担及其变化趋势比较［J］.中国公共卫生,2023,39(1):57-61.
XIA X Q,ZHAO Y,HAO M X,WANG Y W,WAN X,WANG Z W,et al.Disease burden of anxiety disorders in China in 1990 and 2019:a comparative analysis among global regions with different sociodemographic index［J］.Chin J Public Health,2023,39(1):57-61.
［24］　于洗河,曹鹏,贾欢欢,降海蕊,张景茹,高尚,等.1990—2019年我国及不同SDI水平国家和地区高血压性心脏病疾病负担比较分析［J］.中国卫生经济,2021,40(6):54-57.
YU X H,CAO P,JIA H H,JIANG H R,ZHANG J R ,GAO S,et al.Comparative analysis of the burden of hypertensive heart disease in China and countries with different SDI levels from 1990 to 2019［J］.Chin Health Econ,2021,40(6):54-57.

相似文献/References:

[1]李翔 谢钊 郭红建 谢学军 路雪婧 王毅 王超.补肾活血中药对大鼠慢性高眼压模型外侧膝状体病理改变的影响[J].眼科新进展,2012,32(1):000.
[2]范虹 刘五存 蔡鸿英 赵堪兴.改良二极管激光睫状体光凝术治疗中晚期青光眼[J].眼科新进展,2012,32(4):000.
[3]王建萍 赵燕麟 马勇 朱涛 程燕 车选义 赵桂娥 王柯.噻吗洛尔和布林佐胺联合曲伏前列素治疗原发性开角型青光眼与高眼压患者的临床研究[J].眼科新进展,2012,32(5):000.
[4]彭坤 靳隽 杨玉新 许银霞 王保君 闫义涛 杨华.长期联合应用噻吗洛尔对结膜组织炎性标记物ICAM-1和HLA-DR表达的影响[J].眼科新进展,2012,32(6):000.
[5]马恩普 赵小钊 董良 刘苏冰 曾照年.Healaflow在青光眼小梁切除术中的应用[J].眼科新进展,2012,32(6):000.
[6]王勇 叶应嘉 鲍先议 周龑丽 许荣 彭婷婷 曾志富.同轴微小切口超声乳化吸出术在青光眼滤过术后白内障摘出术中的应用[J].眼科新进展,2012,32(7):000.
[7]李翔 马世勇 李娟 王毅.补肾活血中药对大鼠慢性高眼压模型视神经病理改变的影响[J].眼科新进展,2013,33(2):000.
[8]白东娥 刘伟 季建.抗青光眼药物对青光眼患者泪液胰岛素水平的影响及其与眼表改变的关系[J].眼科新进展,2013,33(6):000.
[9]马英慧 张铁民 齐建平.原发性开角型青光眼与慢性原发性闭角型青光眼视网膜神经纤维层厚度与视野缺损的关系[J].眼科新进展,2013,33(7):000.
[10]张海涛 杨玉新 毛永 丁晓丽 秦海霞 梁长华 郭英昌.青光眼与非炎症性缺血型视神经病变的傅立叶OCT扫描视神经形态学对比[J].眼科新进展,2013,33(8):000.

备注/Memo

备注/Memo:
国家自然科学基金青年基金（编号：82205195）；河南省中医临床研究基地科研专项（编号：2022JDZX127）
更新日期/Last Update: 2024-05-05